Amgen AMGN Stock
Amgen Price Chart
Amgen AMGN Financial and Trading Overview
| Amgen stock price | 439.33 USD |
| Previous Close | 431.21 USD |
| Open | 431.71 USD |
| Bid | 437.47 USD x 100 |
| Ask | 433.67 USD x 100 |
| Day's Range | 429.38 - 440.51 USD |
| 52 Week Range | 269.77 - 443.2 USD |
| Volume | 1.88M USD |
| Avg. Volume | 2.7M USD |
| Market Cap | 237.68B USD |
| Beta (5Y Monthly) | 0.413 |
| PE Ratio (TTM) | 27.304537 |
| EPS (TTM) | 16.08 USD |
| Forward Dividend & Yield | 10.08 (2.31%) |
| Ex-Dividend Date | August 21, 2026 |
| 1y Target Est | 388.48 USD |
AMGN Valuation Measures
| Enterprise Value | 277.8B USD |
| Trailing P/E | 27.304537 |
| Forward P/E | 18.007105 |
| PEG Ratio (5 yr expected) | 2.32 |
| Price/Sales (ttm) | 6.239074 |
| Price/Book (mrq) | 20.320536 |
| Enterprise Value/Revenue | 7.292 |
| Enterprise Value/EBITDA | 16.088 |
Trading Information
Amgen Stock Price History
| Beta (5Y Monthly) | 0.413 |
| 52-Week Change | 47.66% |
| S&P500 52-Week Change | 18.15% |
| 52 Week High | 443.2 USD |
| 52 Week Low | 269.77 USD |
| 50-Day Moving Average | 376.93 USD |
| 200-Day Moving Average | 352.12 USD |
AMGN Share Statistics
| Avg. Volume (3 month) | 2.7M USD |
| Avg. Daily Volume (10-Days) | 2.36M USD |
| Shares Outstanding | 541M |
| Float | 539.16M |
| Short Ratio | 5.66 |
| % Held by Insiders | 0.22% |
| % Held by Institutions | 85.11% |
| Shares Short | 13.28M |
| Short % of Float | 2.46% |
| Short % of Shares Outstanding | 2.45% |
Dividends & Splits
| Trailing Annual Dividend Rate | 9.8 |
| Trailing Annual Dividend Yield | 2.27% |
| 5 Year Average Dividend Yield | 307.00% |
| Payout Ratio | 0.6087 |
| Last Split Factor | 2:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 22.95% |
| Operating Margin (ttm) | 35.54% |
| Gross Margin | 71.89% |
| EBITDA Margin | 45.32% |
Management Effectiveness
| Return on Assets (ttm) | 8.66% |
| Return on Equity (ttm) | 91.47% |
Income Statement
| Revenue (ttm) | 38.09B USD |
| Revenue Per Share (ttm) | 70.68 USD |
| Quarterly Revenue Growth (yoy) | 9.50% |
| Gross Profit (ttm) | 27.39B USD |
| EBITDA | 17.27B USD |
| Net Income Avi to Common (ttm) | 8.74B USD |
| Diluted EPS (ttm) | 16.09 |
| Quarterly Earnings Growth (yoy) | 65.90% |
Balance Sheet
| Total Cash (mrq) | 13.99B USD |
| Total Cash Per Share (mrq) | 25.88 USD |
| Total Debt (mrq) | 57.3B USD |
| Total Debt/Equity (mrq) | 490.28 USD |
| Current Ratio (mrq) | 1.371 |
| Book Value Per Share (mrq) | 21.62 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 12.48B USD |
| Levered Free Cash Flow (ttm) | 8.65B USD |
Profile of Amgen
| Country | United States |
| State | CA |
| City | Thousand Oaks |
| Address | One Amgen Center Drive |
| ZIP | 91320-1799 |
| Phone | 805 447 1000 |
| Website | https://www.amgen.com |
| Industry | Drug Manufacturers - General |
| Sector(s) | Healthcare |
| Full Time Employees | 31500 |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Q&A For Amgen Stock
What is a current AMGN stock price?
Amgen AMGN stock price today per share is 439.33 USD.
How to purchase Amgen stock?
You can buy AMGN shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Amgen?
The stock symbol or ticker of Amgen is AMGN.
Which industry does the Amgen company belong to?
The Amgen industry is Drug Manufacturers - General.
How many shares does Amgen have in circulation?
The max supply of Amgen shares is 540.63M.
What is Amgen Price to Earnings Ratio (PE Ratio)?
Amgen PE Ratio is 27.32151600 now.
What was Amgen earnings per share over the trailing 12 months (TTM)?
Amgen EPS is 16.08 USD over the trailing 12 months.
Which sector does the Amgen company belong to?
The Amgen sector is Healthcare.
Amgen AMGN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26180.46 USD — |
+0.43
|
6.32B USD — | 26049.3 USD — | 26269.85 USD — | — - | 6.32B USD — |
|
S&P 500 INDEX
SPX
US
|
7674.37 USD — |
+0.43
|
2.75B USD — | 7660.06 USD — | 7697.11 USD — | — - | 2.75B USD — |
|
S&P 500 (Yahoo.com)
GSPC
US
|
7674.37 USD — |
+0.43
|
2.74B USD — | 7660.06 USD — | 7697.11 USD — | — - | 2.74B USD — |
|
S&P 100
SP100
US
|
3780.07 USD — |
+0.4
|
1.17B USD — | 3770.45 USD — | 3794.1 USD — | — - | 1.17B USD — |
|
US100
NDX
US
|
29308.86 USD — |
+0.33
|
1.14B USD — | 29142.44 USD — | 29405.12 USD — | — - | 1.14B USD — |
|
Dow Jones Industrial Average
DJI
US
|
53277.01 USD — |
+0.98
|
424.07M USD — | 52768.87 USD — | 53355.92 USD — | — - | 424.07M USD — |
|
Dow Jones U.S. Biotechnology In
DJUSBT
US
|
3687.92 USD — |
+1.32
|
166.76M USD — | 3631.54 USD — | 3704.74 USD — | — - | 166.76M USD — |
|
US Tech US Price Setters Index
NQPRCE
US
|
3146.21 USD — |
+0.52
|
— — | 3137.24 USD — | 3151.84 USD — | — - | — — |
|
US Tech-100 After Hours Indicato
QIV
US
|
29318.74 USD — |
+0.36
|
— — | 29294.83 USD — | 29319.57 USD — | — - | — — |
|
US Tech AlphaDEX Multi Cap Growt
NQDXUSMLTCG
US
|
4033.9 USD — |
+0.7
|
— — | 4010.38 USD — | 4037.39 USD — | — - | — — |
|
US Tech CRD Global Sustainabilit
NQCRD
US
|
1735.62 USD — |
0
|
— — | 1715.94 USD — | 1757.95 USD — | — - | — — |
|
US Tech US Broad Dividend Achiev
DAA
US
|
4660.93 USD — |
+0.6
|
— — | 4650.3 USD — | 4669.29 USD — | — - | — — |
|
The Capital Strength Index
NQCAPST
US
|
3710.18 USD — |
+0.71
|
— — | 3692.53 USD — | 3720.33 USD — | — - | — — |
|
Stlmt ID US Tech 100
XQO
US
|
16266.86 USD — |
-0.45
|
— — | 15738.2 USD — | 16639.8 USD — | — - | — — |
|
US Tech-100 ESG Net Notional Tot
NDXESG24
US
|
2292.27 EUR 2646.04 USD |
+0.38
|
— — | 2277.61 EUR 2629.12 USD | 2297.77 EUR 2652.4 USD | — - | — — |
|
US Tech-100 Notional Net Return
XNDXNNREUR
US
|
5255.52 EUR 6066.63 USD |
+0.43
|
— — | 5222.84 EUR 6028.91 USD | 5268.7 EUR 6081.85 USD | — - | — — |
|
US Tech-100 Equal Weighted
NDXE
US
|
10377.05 USD — |
+0.43
|
— — | 10332.09 USD — | 10408.12 USD — | — - | — — |
|
US Tech-100 Total Return
XNDX
US
|
35793.49 USD — |
+0.34
|
— — | 35590.28 USD — | 35911.04 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
|
US Tech Biotechnology Total Retu
XNBI
US
|
7956.6 USD — |
+1.4
|
— — | 7873.47 USD — | 8024.72 USD — | — - | — — |
- {{ link.label }} {{link}}
